Benefits
Caries risk reduction (WB21 PMC4236677)
L. salivarius WB21-containing tablets at 2.0×10^9 CFU/day for 2 weeks significantly DECREASED mutans streptococci counts in saliva (P=0.039) in 8 healthy volunteers (UMIN000013160). Earlier randomized open-label trial compared WB21 + TI 2711 + Ovalgen® DC vs xylitol — mutans streptococci decreased in WB21 group; lactobacilli levels significantly increased. Foundational caries-prevention evidence.
Periodontal health heat-killed CP3365 (PMC10464545)
Heat-killed Ligilactobacillus salivarius CP3365 oral tablet for 8 weeks vs placebo (n=32 per group). Significantly INHIBITED increases in plaque control record + bleeding on probing + probing pocket depth (P<0.05). 16S rRNA: relative abundance of Porphyromonas + Fusobacterium + Haemophilus genera significantly decreased. Postbiotic application — heat-killed organism.
Gut barrier + UCC118 (Collins 2002 + cohort evidence)
Collins et al. 2002 — fermented milk-borne L. salivarius UCC118 in healthy adults significantly INCREASED fecal enterococci and lactobacilli; bifidobacteria, coliforms, bacteroides unchanged. UCC118 expresses surface proteins mediating gut adherence — supporting sustained colonization rather than transient transit. Foundational GI colonization evidence.
CECT5713 immune (Sierra et al.)
L. salivarius CECT5713 in healthy adults INCREASED fecal bifidobacteria with stability of bacteroidetes, clostridia, enterobacteria. Distinguishing immunological strain. Supports microbiota normalization profile.
Ls-33 obesity/gut (Larsen 2013)
L. salivarius Ls-33 evaluated in obese adolescents — preclinical mouse studies classified as anti-inflammatory bacterium with ability to improve gut barrier function. Acceptable safety profile re: colon inflammation + translocation in piglet models.
Strain-specific clinical evidence
STRAIN SPECIFICITY ESSENTIAL — clinical effects are strain-dependent and not extrapolatable across strains. WB21 = oral health; CP3365 = periodontal (heat-killed); LS01/DSM 22775 = atopic dermatitis; CECT5713 = immune; UCC118 = gut barrier; LI01 = liver/intestinal inflammation; PS2 = metabolic. Generic 'L. salivarius' supplements may not deliver strain-specific clinical effects.
Surface protein gut adherence
L. salivarius expresses surface proteins mediating adherence to gut epithelium — supports sustained colonization rather than transient transit. Distinguishing colonization mechanism. Foundation for sustained probiotic effects.
Mechanism of action
Strain-specific bioactivity
Different L. salivarius strains have distinct evidence bases (WB21 oral, CP3365 periodontal, UCC118 gut, CECT5713 immune, Ls-33 metabolic). Foundation principle for strain selection — generic species labeling insufficient for clinical translation.
Surface protein gut adherence + colonization
Surface proteins mediate adherence to gut epithelium → sustained colonization vs transient transit. Distinguishing mechanism among Lactobacillus species.
Mutans streptococci reduction (oral)
WB21 + heat-killed CP3365 demonstrate inhibition of cariogenic + periodontal pathogens. Mechanism: competitive exclusion + antimicrobial peptide production.
Lactic acid + bacteriocin production
Lactic acid + bacteriocin-like substances inhibit pathogenic bacteria. Foundation antimicrobial mechanism shared with other Lactobacillus species.
Anti-inflammatory immunomodulation (Ls-33)
Ls-33 classified as anti-inflammatory bacterium in murine models — improves gut barrier function. Mechanism: cytokine modulation supporting commensal flora.
Postbiotic heat-killed activity (CP3365)
Heat-killed L. salivarius CP3365 retains clinical activity (PMC10464545) — postbiotic application. Mechanism: cell wall components + metabolites without live bacteria requirement.
Clinical trials
Randomized open-label clinical trial + short-term administration trial (UMIN000013160).
Open-label trial: WB21 + TI 2711 + Ovalgen® DC vs xylitol. Short-term trial: 8 healthy volunteers received L. salivarius WB21-containing tablets 2.0×10^9 CFU/day for 2 weeks.
WB21 + TI 2711 + Ovalgen® DC groups DECREASED mutans streptococci vs xylitol. Lactobacilli levels significantly increased in WB21 + TI 2711 groups. Salivary buffering capacity significantly increased in TI 2711 (P=0.003) + Ovalgen® DC (P=0.002). Short-term WB21: significantly decreased mutans streptococci (P=0.039). L. salivarius-containing tablets increase resistance to caries risk factors.
Double-blinded randomized placebo-controlled trial (UMIN000045656).
Healthy participants. n=32 per group. Heat-killed Ligilactobacillus salivarius CP3365 oral tablet daily for 8 weeks vs placebo. In vitro selection based on inhibitory activity against Porphyromonas gingivalis + Fusobacterium nucleatum.
HKL CP3365 significantly (P<0.05) DECREASED viability of oral bacteria in vitro. 8-week clinical: significantly INHIBITED increases in plaque control record + bleeding on probing + probing pocket depth (P<0.05). 16S rRNA: relative abundance of Porphyromonas + Fusobacterium + Haemophilus genera significantly decreased. Useful for maintaining periodontal health.
Randomized controlled trial (Larsen 2013).
Obese adolescents. L. salivarius Ls-33 vs placebo.
Foundational fecal microbiota evidence with Ls-33 in obese adolescents. Murine models classify Ls-33 as anti-inflammatory bacterium with gut barrier improvement ability + acceptable safety profile re: colon inflammation + translocation in piglet models.
About this ingredient
LACTOBACILLUS SALIVARIUS (recently reclassified as LIGILACTOBACILLUS SALIVARIUS) is a probiotic species with MULTIPLE STRAIN-SPECIFIC clinical applications across oral health, gut barrier, immune support, atopic dermatitis, metabolic health, and intestinal inflammation. STRAIN SPECIFICITY ESSENTIAL — generic 'L. salivarius' supplements may not deliver strain-specific clinical effects.
KEY STRAINS: WB21 (oral health, caries reduction); CP3365 (heat-killed, periodontal health); UCC118 (gut barrier, fermented milk); CECT5713 (immune support); Ls-33 (obesity/gut barrier); LS01/DSM 22775 (atopic dermatitis); LI01 (liver-related/intestinal inflammation); PS2 (metabolic). PIVOTAL CLINICAL EVIDENCE: PMC4236677 WB21 randomized open-label trial + short-term 8-volunteer administration (UMIN000013160) — 2.0×10^9 CFU/day for 2 weeks significantly DECREASED mutans streptococci (P=0.039) + earlier comparison vs TI 2711 + Ovalgen® DC + xylitol showed WB21/TI 2711 lactobacilli increases. PMC10464545 heat-killed CP3365 (UMIN000045656) double-blind randomized placebo-controlled 8-week trial in n=64 — significantly inhibited increases in plaque control record + bleeding on probing + probing pocket depth (P<0.05); 16S rRNA: Porphyromonas + Fusobacterium + Haemophilus relative abundance significantly decreased. COLLINS 2002 — fermented milk-borne L. salivarius UCC118 in healthy adults significantly increased fecal enterococci and lactobacilli; bifidobacteria/coliforms/bacteroides unchanged. SIERRA et al. — L. salivarius CECT5713 increased fecal bifidobacteria with stability of bacteroidetes/clostridia/enterobacteria. LARSEN 2013 — Ls-33 fecal microbiota in obese adolescents.
MECHANISMS: STRAIN-SPECIFIC bioactivity (different strains distinct clinical evidence — foundation principle); SURFACE PROTEIN gut adherence (sustained colonization vs transient transit); MUTANS STREPTOCOCCI REDUCTION (oral cariogenic + periodontal pathogen inhibition); LACTIC ACID + BACTERIOCIN production; ANTI-INFLAMMATORY immunomodulation (Ls-33 murine models — gut barrier improvement); POSTBIOTIC heat-killed activity (CP3365 retains clinical activity without live bacteria). EVIDENCE: 3/5 reflects: (1) PMC4236677 WB21 caries risk reduction RCT, (2) PMC10464545 CP3365 heat-killed periodontal RCT (postbiotic application), (3) COLLINS 2002 UCC118 gut barrier evidence, (4) MULTIPLE strain-specific evidence bases (Ls-33, CECT5713, LS01, etc.), (5) STRAIN SPECIFICITY emphasized — generic supplements may not deliver clinical effects, (6) RECENT TAXONOMIC RECLASSIFICATION to Ligilactobacillus salivarius, (7) HEAT-KILLED postbiotic application supports non-viable probiotic context, (8) MULTIPLE INDICATIONS (oral health, periodontal, gut barrier, immune, metabolic, dermatitis), (9) FOOD-GRADE safety profile, (10) higher-evidence than typical Lactobacillus due to strain-specific dedicated research programs. SAFETY: Excellent — multiple multi-week trials + food-grade origin. Best positioned as: (a) ORAL HEALTH adjunct (WB21 caries reduction; CP3365 periodontal), (b) GUT BARRIER support (UCC118), (c) IMMUNE SUPPORT (CECT5713), (d) METABOLIC ADJUNCT in obesity context (Ls-33), (e) ATOPIC DERMATITIS adjunct (LS01/DSM 22775 emerging strain), (f) STRAIN SELECTION ESSENTIAL — choose evidence-based strain matching desired indication, (g) PREGNANCY: food-grade origin supports general safety, (h) IMMUNOCOMPROMISED: caution, (i) ANTIBIOTIC USERS: 2-3 hours apart, (j) higher-evidence than typical Lactobacillus for oral health applications due to dedicated WB21 + CP3365 evidence. Honest framing: L. salivarius has STRONG STRAIN-SPECIFIC evidence across multiple indications but STRAIN SELECTION IS ESSENTIAL — generic 'L. salivarius' supplements may not deliver strain-specific clinical effects. WB21 (oral health), CP3365 (periodontal heat-killed postbiotic), UCC118 (gut), CECT5713 (immune), Ls-33 (metabolic) each have distinct evidence bases. Recent reclassification to Ligilactobacillus salivarius reflects taxonomic update. Heat-killed CP3365 application supports postbiotic context for non-viable probiotic delivery. Reasonable strain-specific adjunct based on multi-strain evidence — particularly compelling for those wanting strain-targeted probiotic for specific indication.